Jane Street’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$315K Sell
7,575
-353
-4% -$14.5K ﹤0.01% 9134
2025
Q4
$306K Sell
7,928
-25,299
-76% -$859K ﹤0.01% 8804
2025
Q3
$907K Buy
+33,227
New +$758K ﹤0.01% 6517
2025
Q2
Sell
-21,149
Closed -$371K 9609
2025
Q1
$371K Buy
+21,149
New +$454K ﹤0.01% 7443
2020
Q1
Sell
-36,323
Closed -$1.38M 5289
2019
Q4
$1.38M Buy
36,323
+9,372
+35% +$279K ﹤0.01% 2367
2019
Q3
$642K Buy
26,951
+7,409
+38% +$201K ﹤0.01% 3199
2019
Q2
$563K Sell
19,542
-13,966
-42% -$390K ﹤0.01% 3427
2019
Q1
$954K Buy
+33,508
New +$878K ﹤0.01% 2860
2018
Q4
Sell
-22,650
Closed -$783K 4924
2018
Q3
$783K Buy
22,650
+9,268
+69% +$313K ﹤0.01% 3069
2018
Q2
$437K Buy
13,382
+3,147
+31% +$103K ﹤0.01% 3731
2018
Q1
$336K Sell
10,235
-13,851
-58% -$452K ﹤0.01% 3895
2017
Q4
$685K Buy
+24,086
New +$674K ﹤0.01% 2801
2017
Q2
Sell
-32,219
Closed -$747K 4314
2017
Q1
$747K Buy
32,219
+4,718
+17% +$100K ﹤0.01% 2429
2016
Q4
$506K Buy
27,501
+589
+2% +$11.7K ﹤0.01% 2851
2016
Q3
$610K Buy
26,912
+11,380
+73% +$233K ﹤0.01% 2547
2016
Q2
$280K Buy
+15,532
New +$305K ﹤0.01% 3402
2015
Q4
Sell
-17,855
Closed -$471K 3978
2015
Q3
$471K Sell
17,855
-39,267
-69% -$1.33M ﹤0.01% 2361
2015
Q2
$2.07M Buy
57,122
+39,905
+232% +$1.37M 0.01% 985
2015
Q1
$565K Buy
17,217
+4,459
+35% +$136K ﹤0.01% 1940
2014
Q4
$354K Buy
+12,758
New +$350K ﹤0.01% 1752

Other funds holding BBC

Jane Street's BBC Position: Q1 2026 in Review

Jane Street reduced its Virtus Biotech Clinical Trials ETF (BBC) stake by 4.5% in Q1 2026, selling an estimated $14.5K and leaving 7,575 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #9134.

Jane Street first reported a position in BBC in Q4 2014 and has held it in 20 quarters since. The position peaked at $2.07M in Q2 2015. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

  • Jane Street held 7,575 shares of Virtus Biotech Clinical Trials ETF worth $315K as of Q1 2026.
  • Jane Street sold 353 Virtus Biotech Clinical Trials ETF shares in Q1 2026, an estimated $14.5K.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #9134 holding.
  • Jane Street first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2014 and has held it in 20 quarters since.
  • Jane Street's Virtus Biotech Clinical Trials ETF position peaked at $2.07M in Q2 2015.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.